Cantex Reviews Potential Prostate Cancer Therapy CX-02 at Recent World Orphan Drug Congress

Cantex Reviews Potential Prostate Cancer Therapy CX-02 at Recent World Orphan Drug Congress
Cantex Pharmaceuticals gave an overview of its lead candidate anti-cancer drug CX-02 at last week’s World Orphan Drug Congress USA in Washington, D.C. Cantex is a clinical-stage biopharma company that develops and markets therapies to treat cancer and other life-threatening diseases. Based in Weston, Fla., it uses proprietary modifications and applies them to well-known drugs that have been proven safe

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *